News
- Author:
- Bruce Jancin
Publish date: October 3, 2019
PARIS – “Be aware, be careful, and provide appropriate antibiotic prophylaxis, just as surgeons do in SAVR,” said Dr. Laurent Fauchier.
Video
- Author:
- Bruce Jancin
Publish date: October 3, 2019
PARIS – Three-quarters of patients who presented with suspected acute coronary syndrome were safely discharged from ED without hospital admission.<...
News
- Author:
- Bruce Jancin
Publish date: October 1, 2019
PARIS – Insufficient physical activity is a much stronger predictor of adverse outcomes after a first MI than is ...
News
- Author:
- Bruce Jancin
Publish date: October 1, 2019
PARIS – The current echocardiographic definition of moderate aortic stenosis may greatly underestimate risk.
News
- Author:
- Bruce Jancin
Publish date: September 30, 2019
STOCKHOLM – “It’s good for neurologists to know that, if they prescribe cannabis or their patient is self-medicating and chooses to stop, their cog...
News
- Author:
- Bruce Jancin
Publish date: September 26, 2019
COPENHAGEN – Maternal somatic anxiety during pregnancy and toddlerhood increases a child’s risk of hyperactivity symptoms in adolescence.
News
- Author:
- Bruce Jancin
Publish date: September 25, 2019
COPENHAGEN – One-quarter of patients showed clinically meaningful weight reduction.
News
- Author:
- Bruce Jancin
Publish date: September 25, 2019
PARIS – Giving high-flow supplemental oxygen to nonhypoxemic patients with suspected ACS is without any clinical ...
News
- Author:
- Bruce Jancin
Publish date: September 24, 2019
COPENHAGEN – Three days of wearing blue light–blocking glasses brought major clinical improvements in an RCT.
News
- Author:
- Bruce Jancin
Publish date: September 20, 2019
COPENHAGEN – This noninvasive therapy can stimulate brain targets 3-5 cm below the skull, unlike standard TMS.
News
- Author:
- Bruce Jancin
Publish date: September 18, 2019
COPENHAGEN – Primary endpoint met in two phase 3 pivotal trials in patients with major depressive disorder symptoms at imminent risk for suicide.
News
- Author:
- Bruce Jancin
Publish date: September 17, 2019
PARIS – This large randomized trial was called practice changing.
News
- Author:
- Bruce Jancin
Publish date: September 16, 2019
STOCKHOLM – Biggest-ever study of natalizumab-associated PML in patients with multiple sclerosis raises red flag regarding common practice of plasm...
News
- Author:
- Bruce Jancin
Publish date: September 15, 2019
STOCKHOLM – Study from U.S. Network of Pediatric MS Centers supports early use of newer disease-modifying therapies.
News
- Author:
- Bruce Jancin
Publish date: September 13, 2019
STOCKHOLM – The conversion rate jumps to 87% in the presence of four risk factors at baseline.
